An expert panel voted unanimously to remove the FDA approval for Bavacizumab (Avastin) in treatment of breast cancer. It’s important to note that it is still approved for use in Lung Cancer (non-small cell lung cancer patients who have not gotten treatment), kidney cancer as combination treatment), some brain cancer (Glioblastoma where the cancer has progressed after previous treatment) and colorectal cancer that has spread (is metastatic). Avastin works to cut off the ability of some cancer to create a blood supply (blocks VEGF or vascular endothelial growth factor). This works to starve the tumor.
The special committee met in Silver Spring, Maryland on June 29th to decide if a recommendation to revoke the prior FDA approval should be made. While the conclusion is NOT binding for the FDA, the expert panel voted 6 to zero that that approval for use as a breast cancer treatment should be revoked.